Sanofi to Buy Hemophilia Specialist Bioverativ

09:17 EST 24 Jan 2018 | CHEManager

Sanofi is boosting its presence in blood disorders through the acquisition of Bioverativ, the former hemophilia business of major US biotech Biogen, which was spun out in February 2017.

Original Article: Sanofi to Buy Hemophilia Specialist Bioverativ


More From BioPortfolio on "Sanofi to Buy Hemophilia Specialist Bioverativ"

Quick Search


Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...